![](https://morganandmendel.com/wp-content/uploads/2021/10/Mission_arrow.png)
To lead the next generation of genomic risk assessment testing using novel flow cytometry-based technologies and deliver faster, more accurate and less expensive results than sequencing
![](https://morganandmendel.com/wp-content/uploads/2021/10/Purpose-Arrow.png)
To commercialize highly accurate, low-cost genetic tests to assess risk for cancer and to assess their candidacy for certain therapies